Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 21 |
| Active Pipeline (Recruiting Now) | 0 (0) |
| Completed vs Stopped Early | 17 / 4 (19.1%) |
| Median Closed Actual Enrollment | 1,358 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05519839 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Novavax Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.